Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases

BACKGROUND AND AIMS: Despite proven clinical efficacy of vedolizumab (VDZ) for inducing and maintaining remission in patients with Crohn’s disease (CD) and ulcerative colitis (UC), subgroups of patients have no therapeutic benefit from anti-α4β7 integrin therapy with VDZ. Within this study, we aimed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Immunol
Main Authors: Rath, Timo, Billmeier, Ulrike, Ferrazzi, Fulvia, Vieth, Michael, Ekici, Arif, Neurath, Markus F., Atreya, Raja
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6090141/
https://ncbi.nlm.nih.gov/pubmed/30131801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01700
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados